Scarica l'app Stockscreener
14.76
4.24%
0.60
Dopo l'orario di chiusura:
14.72
-0.04
-0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.16
Aprire:
$14.22
Volume 24 ore:
1.57M
Relative Volume:
1.45
Capitalizzazione di mercato:
$679.15M
Reddito:
$159.01M
Utile/perdita netta:
$-21.72M
Rapporto P/E:
-28.38
EPS:
-0.52
Flusso di cassa netto:
$-20.63M
1 W Prestazione:
+7.35%
1M Prestazione:
+24.14%
6M Prestazione:
-18.63%
1 anno Prestazione:
+31.08%
Intervallo 1D:
$14.00
$14.76
Intervallo di 1 settimana:
$13.50
$14.76
Portata 52W:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
Nome
Axogen Inc
Settore
Industria
Telefono
(386) 462-6817
Indirizzo
13631 PROGRESS BLVD., ALACHUA, FL
Confronta AXGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
14.76 | 644.64M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
129.40 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | Lake Street | Buy |
| 2024-07-01 | Iniziato | Raymond James | Outperform |
| 2022-11-11 | Ripresa | Jefferies | Buy |
| 2022-05-09 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | Guggenheim | Buy |
| 2020-06-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Iniziato | Canaccord Genuity | Buy |
| 2018-03-02 | Reiterato | Lake Street | Buy |
| 2018-01-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Iniziato | Jefferies | Buy |
| 2017-11-21 | Reiterato | Lake Street | Buy |
| 2017-07-31 | Iniziato | Leerink Partners | Outperform |
| 2017-06-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Iniziato | ROTH Capital | Buy |
| 2016-11-22 | Aggiornamento | Lake Street | Hold → Buy |
| 2016-11-07 | Reiterato | Wedbush | Outperform |
| 2016-11-03 | Downgrade | Lake Street | Buy → Hold |
| 2016-08-04 | Reiterato | Wedbush | Outperform |
| 2014-05-14 | Iniziato | Dawson James | Buy |
| 2013-10-31 | Reiterato | Ladenburg Thalmann | Buy |
Mostra tutto
Axogen Inc Borsa (AXGN) Ultime notizie
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Insider Monkey
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - Yahoo Finance
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com Australia
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Transcript : Axogen, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Axogen Boosts 2025 Revenue Growth Target to at Least 17% Ahead of BLA Approval. - AInvest
Axogen, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) - Seeking Alpha
Axogen (AXGN.O) Sees Sharp Intraday Spike—What’s Driving the Volatility? - AInvest
AxoGen's Q2 Earnings Exceed Expectations with Strong Financial TurnaroundNews and Statistics - IndexBox
Axogen Stock Soars 18.25% on Strong Q2 Earnings - AInvest
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
AxoGen Q2 revenue up 18.3%, beats estimates - MarketScreener
Axogen Inc earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Axogen's Q2 2025 Financial Outlook and Strategic Position in the Peripheral Nerve Repair Market - AInvest
Axogen, Inc. Reports Second Quarter 2025 Financial Results - The Manila Times
Should I hold or sell Axogen Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
Is it the right time to buy Axogen Inc. stockBreakthrough stock performance - Jammu Links News
Is Axogen Inc. a good long term investmentCapitalize on emerging investment opportunities - Jammu Links News
What catalysts could drive Axogen Inc. stock higher in 2025Spectacular growth rates - Jammu Links News
What institutional investors are buying Axogen Inc. stockConsistently high returns - Jammu Links News
What is the dividend policy of Axogen Inc. stockUnlock powerful market trend analysis - Jammu Links News
What are Axogen Inc. company’s key revenue driversAchieve consistent profits with expert advice - Jammu Links News
What markets is ENTX expanding into Is Axogen Inc. stock a good long term investment optionRemarkably fast returns - Jammu Links News
What are the latest earnings results for Axogen Inc.Build a strong portfolio for growth and safety - Jammu Links News
Axogen Inc Azioni (AXGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):